Can Eli Lilly Stock Withstand the Threat of President Trump's New Sweeping Tariffs?

The active ingredients of roughly 80% of prescription drugs sold in the U.S. are made in other countries. President Trump wants that to change. Instead of a carrot-and-stick approach, the president plans to rely solely on a stick -- tariffs. Trump recently threatened to levy steep tariffs on all pharmaceutical imports to the United States. As you might expect, the pharmaceutical industry doesn't like the idea. But can a top pharma stock such as Eli Lilly (NYSE: LLY) withstand the threat of Trump's new sweeping tariffs? Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool